TNFRSF8 and lymphoma: A clinical trial with gene-modified third-party partially HLA-matched healthy donor-derived banked CAR+ EBVSTs targeting CD30 in patients with EBV-associated CD30+ lymphomas is in preparation at Baylor College of Medicine (NCT04288726).